Johnson & Johnson Family of Companies
NEWS
This summer, BioSpace will release a series of reports looking at the current state of diversity and inclusion in the life sciences.
Janssen’s Tremfya, an IL-23 inhibitor, is showing an ability to separate itself from AbbVie’s Skyrizi in preventing the activation of cells that drive inflammation.
An investigation conducted by the U.S. House of Representatives shows Emergent was forced to destroy nearly 400 million doses of the vaccine. The company disputes the report’s claim.
Three long-time FDA officials, Dr. Peter Marks, Dr. Janet Woodcock and Dr. Robert Califf wrote an op-ed in JAMA describing the reality that COVID-19 represents “the new normal.”
Teva announced that it had reached a deal with Lupin over Lupin’s Abbreviated New Drug Application (ANDA) for generic deutetrabenazine - an upcoming competitor to Hungtington’s drug Austedo.
Emergent BioSolutions Founder and former chief executive officer Fuad El-Hibri has died, the company reported.
Gilead’s Veklury made massive profits, but as more vaccine boosters arrive and more people become immune to the virus, the future of the antiviral is in question.
Zymeworks received an unsolicited, non-binding acquisition offer from global investment firm All Blue Capital. All Blue is offering $10.50 per share for a total of $773 million in cash.
Weeks after Gilead Sciences raised concern over counterfeit HIV drugs, Johnson & Johnson has taken similar action against the distribution of counterfeit prescription drugs.
JOBS
IN THE PRESS